Advanced search
Publication Cover
Journal of Medical Economics Volume 24, 2021 - Issue 1
Submit an article Journal homepage
5,300
Views
8
CrossRef citations to date
0
Altmetric
Hematology

Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model

Nanxin Lia uniQure Inc, Lexington, MA, USACorrespondence[email protected]
,
Eileen K. Sawyera uniQure Inc, Lexington, MA, USA
,
Konrad Maruszczykb HCD Economics, Daresbury, UKORCID Iconhttps://orcid.org/0000-0002-0173-5020
ORCID Icon,
Greg Guzauskasb HCD Economics, Daresbury, UK;c CHOICE Institute, University of Washington, Seattle, WA, USAORCID Iconhttps://orcid.org/0000-0002-9095-1672
ORCID Icon,
Marta T. Slomkab HCD Economics, Daresbury, UK;d Mossakowski Medical Research Centre PAS, Warsaw, Poland
,
Tom Burkeb HCD Economics, Daresbury, UK
,
Antony P. Martinb HCD Economics, Daresbury, UKORCID Iconhttps://orcid.org/0000-0003-4383-6038
ORCID Icon,
Jamie O’Harab HCD Economics, Daresbury, UK;e Faculty of Health and Social Care, University of Chester, Chester, UKORCID Iconhttps://orcid.org/0000-0001-8262-034X
ORCID Icon,
Matt Stevensonf School of Health and Related Research, The University of Sheffield, Sheffield, UKORCID Iconhttps://orcid.org/0000-0002-3099-9877
ORCID Icon &
Michael Rechtg American Thrombosis and Hemostasis Network, Rochester, NY, USA;h The Hemophilia Center, Oregon Health & Science University, Portland, OR, USAORCID Iconhttps://orcid.org/0000-0002-2805-1016
ORCID Icon show all
Pages 363-372 | Received 21 Dec 2020, Accepted 12 Feb 2021, Published online: 02 Mar 2021

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Maria Elisa Mancuso, Daniel Eriksson, Aletta Falk, Zalmai Hakimi, Piotr Wojciechowski, Marlena Wdowiak & Robert Klamroth. (2023) Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials. Journal of Blood Medicine 14, pages 427-434.
Read now

Articles from other publishers (7)

Antal Zemplenyi, Jim Leonard, Michael J. DiStefano, Kelly E. Anderson, Garth C. Wright, Nicholas D. Mendola, Kavita Nair & R. Brett McQueen. (2023) Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid. PharmacoEconomics.
Crossref
Andrea Guala & Emilia Parodi. (2023) Il farmaco più costoso del mondo. Medico e Bambino 42:7, pages 415-416.
Crossref
Bertrand Jordan. (2023) Une thérapie très attendue… et un prix exorbitant !. médecine/sciences 39:2, pages 187-190.
Crossref
Simon Fletcher, Kathryn Jenner, Luke Pembroke, Michael Holland & Kate Khair. (2022) The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study. Orphanet Journal of Rare Diseases 17:1.
Crossref
Kristen Corrao & Lynn Malec. (2022) Disease Eradication for Hemophilia: How and Who. The Hematologist 19:6.
Crossref
Pratima ChowdarySusan ShapiroMike MakrisGillian EvansSara BoyceKate TalksGerard DolanUlrike ReissMark PhillipsAnne RiddellMaria R. PeraltaMichelle QuayeDavid W. PatchEdward TuddenhamAllison DaneMarie WatisséeAlison LongAmit Nathwani. (2022) Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B. New England Journal of Medicine 387:3, pages 237-247.
Crossref
Courtney D. Thornburg. (2021) Etranacogene dezaparvovec for hemophilia B gene therapy. Therapeutic Advances in Rare Disease 2, pages 263300402110588.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.